ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

226
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
Refresh
08 Nov 2017 20:24

Genomics as an Investment Theme

Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...

Logo
305 Views
Share
bearishDaiichi Sankyo
14 Sep 2017 07:49

Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017

Daiichi Sankyo [DSK] (4568 JP) released Phase I data for DS-8201 at ESMO 2017 as follows: 32% overall response rate, 82% disease control rate. The...

13 Sep 2017 22:59

Biosimilar Battlefield: Samsung Bioepis Forecast

This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...

Share
bullishPeptidream Inc
11 Apr 2017 21:53

PeptiDream: J&J Latest Drug Major to Tie Up

On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...

10 Apr 2017 16:15

Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs

Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...

x